Found 189 results in Expert Content

The development of orally administered small molecules is more challenging as an many have poor aqueous solubility and bioavailability.

Summary: Characterize lead molecules and develop the best pathway to bring them to Phase I studies and beyond.

Summary: Thousands of drug candidates are abandoned annually due to solubility and bioavailability issues, but advanced formulation technologies can profoundly impact how a drug compound...

This webinar focuses on the key considerations for transitioning small molecules from preclinical through clinical development.

Summary: Recorded at Manufacturing Chemist Live 2020, this presentation discusses some of the key issues to consider when planning for the scale-up of a small molecule development program.

Summary: Dramatically shifting the attention of the industry, Covid-19 forced orphan developers to re-examine their go-to-market strategies.

Summary: Dramatically shifting the attention of the industry, Covid-19 forced orphan developers to re-examine their go-to-market strategies.

Summary: Low bioavailability can lead to development challenges. Advanced formulation expertise and technologies can increase the chance of success in the clinic.

Summary: Jeremy Trochu, Vice President and General Manager of Pharmaceutical Development Services at Catalent, recently sat down for an interview...

Summary: Big Pharma used to ignore this segment of the market, but now developing orphan drugs to treat these rare diseases is an industry priority.